A groundbreaking vaccine which may finally beat Streptococcus A infections has been developed at Griffith University’s Institute for Glycomics.
Human trials are to begin next year for the vaccine which combines the protein, SpyCEP, with a previously developed vaccine J8-DT.
Infections caused by Streptococcus pyogenes are responsible for the deaths of almost 500,000 people worldwide each year.
It is particularly prevalent in developing countries and Indigenous populations, including Aboriginal people and Torres Strait Islanders.
Infections can range from tonsillitis and what is commonly known as schools sores to life threatening diseases where deep tissues are infected.
Professor Michael Good, principal research leader at the Institute for Glycomics, says the research, in the Journal of Immunology, shows the team is close to beating Strep A once and for all.
“We have successfully vaccinated mice with a vaccine that we believe will be suitable for humans,” he said.
“We will spend the next six months developing that vaccine at a high level of purity suitable for humans and hope to start a clinical trial next year.”
NOW WATCH: Briefing videos
Business Insider Emails & Alerts
Site highlights each day to your inbox.